Physician profile
Cara E O'Brien
NPI 1992414437
$4,696.29
in general payments reported to CMS, 2019-2025
42 companies · $900 in 2025
The $900 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,189 · 2024: $1,607 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,497 · Education: $99.99 · Long Term Medical Supply Or Device Loan: $99.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,496.60 |
| Education | $99.99 |
| Long Term Medical Supply Or Device Loan | $99.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $746.68 | 2023-2025 | Calquence, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $406.66 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $383.51 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $267.79 | 2023-2024 | Opdivo, Reblozyl |
| Eisai INC. | $261.22 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $249.94 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $197.62 | 2023-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Pfizer INC. | $191.72 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $136.06 | 2023-2024 | Libtayo |
| Genzyme Corporation | $135.04 | 2023-2024 | |
| Lilly USA, LLC | $128.89 | 2023-2024 | Verzenio, Retevmo, Jaypirca |
| Seagen INC. | $122.95 | 2023-2024 | Padcev |
| Daiichi Sankyo INC. | $96.75 | 2023-2025 | Enhertu |
| Kite Pharma, INC. | $96.53 | 2023 | |
| Fresenius Kabi USA, LLC | $92.41 | 2023-2025 | Stimufend |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $83.16 | 2024-2025 | Zejula, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $82.39 | 2023-2025 | |
| Beigene USA, INC. | $76.80 | 2023-2025 | Brukinsa |
| Amneal Pharmaceuticals LLC | $68.81 | 2023-2025 | Avastin, Alymsys |
| Gilead Sciences, INC. | $65.99 | 2023-2024 | Trodelvy |
| Incyte Corporation | $59.85 | 2023-2025 | Jakafi, Monjuvi |
| Morphosys, US INC. | $58.36 | 2023 | Monjuvi |
| Aveo Pharmaceuticals, INC. | $54.78 | 2024-2025 | |
| Tersera Therapeutics LLC | $54.22 | 2025 | Xermelo, Zoladex |
| Springworks Therapeutics, INC. | $53.28 | 2024 | Ogsiveo |
| Celltrion USA INC. | $52.18 | 2023-2024 | Vegzelma |
| Sumitomo Pharma America, INC. | $50.58 | 2023 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $48.86 | 2024-2025 | Ultomiris |
| Celgene Corporation | $45.45 | 2025 | Reblozyl, Breyanzi |
| Astellas Pharma US INC | $42.59 | 2024 | Padcev |
| Abbvie INC. | $36.75 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $32.28 | 2025 | Qinlock, Romvimza |
| Servier Pharmaceuticals LLC | $23.86 | 2023 | |
| Myriad Genetic Laboratories, INC. | $23.63 | 2023 | Myrisk |
| Puma Biotechnology, INC. | $23.61 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.33 | 2024 | |
| G1 Therapeutics, INC. | $23.12 | 2023 | Cosela |
| Adc Therapeutics America, INC. | $21.83 | 2023 | |
| Genentech USA, INC. | $21.83 | 2023 | Avastin, Tecentriq |
| Fennec Pharmaceuticals, INC. | $20.36 | 2024 | Pedmark |
| Pharmacosmos Therapeutics INC. | $17.63 | 2024 | Cosela |
| Array Biopharma INC | $16.99 | 2024 | Braftovi, Mektovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara O'Brien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.